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A B S T R A C T
Invasive aspergillosis is an increasingly common disease. While there have been significant advances in
the past decade, significant challenges remain in terms of diagnosis and therapy. Some of the recent
advances are outlined and future opportunities to improve the unacceptable mortality that is currently
associated with this infection are considered.
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In the last decade, there have been significant
advances in the diagnosis and treatment of
invasive aspergillosis. For example, a recent trial
demonstrated a superior response rate and sur-
vival advantage for patients with invasive asper-
gillosis receiving voriconazole as compared with
deoxycholate amphotericin B [1]. While this is
encouraging, significant challenges remain, since
the incidence of the disease is increasing and,
despite best current practices, the mortality rate
remains unacceptably high at 30–50% [1,2].
The trial of voriconazole and deoxycholate
amphotericin B [1] was conducted in immuno-
compromised patients with proven and probable
invasive aspergillosis. With use of a 12-week
endpoint, a successful outcome was demonstra-
ted in 52.8% of patients receiving voriconazole, as
compared with 31.9% of those receiving ampho-
tericin B [1]. A mortality advantage was also
observed in patients receiving voriconazole; this
is the first such report in an antifungal treatment
trial. Despite concerns about differing durations
of therapy, as well as the possibility of excessive
interruptions in the amphotericin arm [3], the
conclusion that voriconazole is superior to amph-
otericin B for treatment of invasive aspergillosis
has been welcomed by most clinicians. What are
the exceptions and what insights into invasive
aspergillosis does the trial provide?
Voriconazole, despite its clear efficacy, may not
always be appropriate, since drug toxicity, inter-
actions with other drugs, resistance and polymi-
crobial fungal infections all represent scenarios
where its use is either contraindicated or unlikely
to be unsuccessful.
Higher than anticipated levels of voriconazole
may be seen in elderly patients [4], patients with
hepatic impairment [4], or those with a genetic
deficiency of the cytochrome P450 enzyme
CYP2C19, which is the most important of three
human cytochromes involved in voriconazole
metabolism [4,5]. CYP2C19 polymorphisms
appear to account for most interpatient variability
in voriconazole levels [4,5], and a deficiency
of this enzyme is seen in 5% of caucasians and
10–20% of Asians [4]. Where toxicity is of con-
cern, voriconazole should be used only if the
benefits outweigh the risks. In the situation of
CYP2C19 polymorphisms, the only strategy to
prevent toxicity is to systematically measure
serum voriconazole levels, although this is not
widely advocated at present.
Drug interactions represent a further obstacle
to the routine use of voriconazole. For example,
rifampicin induces enzymes responsible for vor-
iconazole metabolism, so that efficacious levels
are unobtainable [4]. In contrast, voriconazole
potentially inhibits the metabolism of several
drugs, with potentially serious toxic conse-
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quences, including astemizole, terfenadine, cisa-
pride, and sirilomus [4,6], while others can be
co-administered but require dose adjustments.
This latter group includes tacrolimus, cyclosporin
and warfarin [4].
Primary resistance of Aspergillus spp. to vor-
iconazole appears to be uncommon [7] and
currently does not influence the therapeutic
decision. The rate of development of secondary
resistance is unknown, but requires considera-
tion when patients either fail voriconazole or
have significant pre-exposure. Although des-
cribed [8], cross-resistance with itraconazole
does not appear to be common [9], and therefore
itraconazole may be useful for salvage therapy
in such situations.
Finally, documented or possible polymicrobial
infections with yeasts or other filamentous fungi
resistant to voriconazole (e.g., the Mucorales) also
compromise routine use of voriconazole as
monotherapy.
Is the benefit exhibited by voriconazole a class
effect of azoles, and can the results be extrapola-
ted to other azoles with activity against Aspergillus
spp.? This is a complex question, and difficult to
answer in the absence of comparative clinical
trials. The azoles share a common fungal target,
i.e., P450-dependent 14a-demethylase. However,
their clinical utility as anti-Aspergillus agents
probably also depends on other factors, such as
fungicidality, pharmacokinetic characteristics,
compartmental pharmacokinetics, protein bind-
ing (and therefore free drug available), and the
presence or absence of active metabolites, to
name a few. These parameters vary considerably
between agents, and between individuals, making
comparisons complicated. Until further evidence
is available, it seems that voriconazole should be
used in preference to other azoles for invasive
aspergillosis. Additional questions include the
possible role of the echinocandins as primary
agents, combinations of antifungal agents, and the
appropriate sequence of antifungal regimens. The
sequence of itraconazole and amphotericin B is
probably detrimental [10], but it is not clear if this
pertains to all azoles.
Diagnostic issues remain of paramount
importance and relevance for invasive aspergil-
losis. A major challenge is how to incorporate
diagnostic tests such as PCR and antigen tests
into published criteria. Lack of test standardisa-
tion, difficulties in establishing the reference
standard, differences in test performance in
different situations, and understanding how tests
apply to different stages of the infectious process
from colonisation through to tissue damage,
represent substantial but not insurmountable
obstacles to this process.
The development of diagnostic criteria has
been conceptually difficult, so the recently pub-
lished criteria for patients with haematological
malignancy, cancer and bone marrow transplan-
tation [11] represent a welcome advance, with
subtle differences from other diagnostic criteria.
Thus, the voriconazole trial allowed a halo or
air-crescent sign to define probable invasive
aspergillosis without any additional microbiolo-
gical evidence in the setting of haematological
malignancy, neutropenia or allogeneic bone mar-
row transplantation, but this is now deemed to
be inadequate [11]. In the voriconazole trial, a
halo or air-crescent sign without supporting
microbiological evidence was previously classi-
fied in the same manner as a lung biopsy
demonstrating hyphae consistent with Aspergillus
spp. with no supporting microbiological evi-
dence, despite the fact that the two may differ in
terms of their positive predictive value for
invasive aspergillosis.
These observations serve to make two points.
First, diagnostic criteria are merely statements
about the probability of a specific underlying
biological process. It is also important that cases
which do not conform to established criteria are
not automatically excluded, but rather considered
on their merits, as long as an understanding is
reached on how they depart from standard
criteria. Second, there are clearly many different
and subtle manifestations of invasive aspergillosis
which have implications for diagnostic tools, in
terms of both their performance and the role they
play in subclassifying invasive aspergillosis.
Diagnostic criteria need to be simple and robust
to achieve widespread acceptance, while remain-
ing flexible enough to identify the subtleties of the
infection and account for its protean manifesta-
tions in a wide range of hosts.
Infections caused by Aspergillus spp. remain
one of the most challenging and exciting areas of
medicine, since they encompass rapidly develop-
ing diagnostic and therapeutic modalities. The
ultimate aim is to minimise morbidity and mor-
tality in a disease which has been notoriously
difficult to diagnose and treat.
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